Christophe Barba1,2, Christophe O Soulage1, Gianvito Caggiano3, Griet Glorieux4, Denis Fouque1,2, Laetitia Koppe1,2. 1. CarMeN Lab, INSA-Lyon, INSERM U1060, INRA, University Claude Bernard Lyon 1, 69100 Villeurbanne, France. 2. Department of Nephrology, Hospices Civils de Lyon, Lyon Sud Hospital, 69310 Pierre Bénite, France. 3. Nephrology, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, 70124 Bari, Italy. 4. Nephrology Section, Department of Internal Medicine and Pediatrics, Ghent University Hospital, 9000 Gent, Belgium.
Abstract
BACKGROUND: Chronic kidney disease (CKD) is a renal disorder characterized by the accumulation of uremic toxins with limited strategies to reduce their concentrations. A large amount of data supports the pivotal role of intestinal microbiota in CKD complications and as a major source of uremic toxins production. Here, we explored whether fecal microbiota transplantation (FMT) could be attenuated in metabolic complication and uremic toxin accumulation in mice with CKD. METHODS: Kidney failure was chemically induced by a diet containing 0.25% (w/w) of adenine for four weeks. Mice were randomized into three groups: control, CKD and CKD + FMT groups. After four weeks, CKD mice underwent fecal microbiota transplantation (FMT) from healthy mice or phosphate buffered saline as control. The gut microbiota structure, uremic toxins plasmatic concentrations, and metabolic profiles were explored three weeks after transplantation. RESULTS: Associated with the increase of alpha diversity, we observed a noticeable improvement of gut microbiota disturbance, after FMT treatment. FMT further decreased p-cresyl sulfate accumulation and improved glucose tolerance. There was no change in kidney function. CONCLUSIONS: These data indicate that FMT limited the accumulation of uremic toxins issued from intestinal cresol pathway by a beneficial effect on gut microbiota diversity. Further studies are needed to investigate the FMT efficiency, the timing and feces amount for the transplantation before, to become a therapeutic option in CKD patients.
BACKGROUND:Chronic kidney disease (CKD) is a renal disorder characterized by the accumulation of uremic toxins with limited strategies to reduce their concentrations. A large amount of data supports the pivotal role of intestinal microbiota in CKD complications and as a major source of uremic toxins production. Here, we explored whether fecal microbiota transplantation (FMT) could be attenuated in metabolic complication and uremic toxin accumulation in mice with CKD. METHODS:Kidney failure was chemically induced by a diet containing 0.25% (w/w) of adenine for four weeks. Mice were randomized into three groups: control, CKD and CKD + FMT groups. After four weeks, CKD mice underwent fecal microbiota transplantation (FMT) from healthy mice or phosphate buffered saline as control. The gut microbiota structure, uremic toxins plasmatic concentrations, and metabolic profiles were explored three weeks after transplantation. RESULTS: Associated with the increase of alpha diversity, we observed a noticeable improvement of gut microbiota disturbance, after FMT treatment. FMT further decreased p-cresyl sulfate accumulation and improved glucose tolerance. There was no change in kidney function. CONCLUSIONS: These data indicate that FMT limited the accumulation of uremic toxins issued from intestinal cresol pathway by a beneficial effect on gut microbiota diversity. Further studies are needed to investigate the FMT efficiency, the timing and feces amount for the transplantation before, to become a therapeutic option in CKD patients.
Authors: Noortje G Rossen; Susana Fuentes; Mirjam J van der Spek; Jan G Tijssen; Jorn H A Hartman; Ann Duflou; Mark Löwenberg; Gijs R van den Brink; Elisabeth M H Mathus-Vliegen; Willem M de Vos; Erwin G Zoetendal; Geert R D'Haens; Cyriel Y Ponsioen Journal: Gastroenterology Date: 2015-03-30 Impact factor: 22.682
Authors: Nosratola D Vaziri; Jakk Wong; Madeleine Pahl; Yvette M Piceno; Jun Yuan; Todd Z DeSantis; Zhenmin Ni; Tien-Hung Nguyen; Gary L Andersen Journal: Kidney Int Date: 2012-09-19 Impact factor: 10.612
Authors: A Sloan Devlin; Angela Marcobal; Dylan Dodd; Stephen Nayfach; Natalie Plummer; Tim Meyer; Katherine S Pollard; Justin L Sonnenburg; Michael A Fischbach Journal: Cell Host Microbe Date: 2016-12-01 Impact factor: 21.023
Authors: Raymond Vanholder; Eva Schepers; Anneleen Pletinck; Evi V Nagler; Griet Glorieux Journal: J Am Soc Nephrol Date: 2014-05-08 Impact factor: 10.121
Authors: Dorothy A Kieffer; Brian D Piccolo; Nosratola D Vaziri; Shuman Liu; Wei L Lau; Mahyar Khazaeli; Sohrab Nazertehrani; Mary E Moore; Maria L Marco; Roy J Martin; Sean H Adams Journal: Am J Physiol Renal Physiol Date: 2016-02-03
Authors: Eke G Gruppen; Erwin Garcia; Margery A Connelly; Elias J Jeyarajah; James D Otvos; Stephan J L Bakker; Robin P F Dullaart Journal: Sci Rep Date: 2017-10-23 Impact factor: 4.379
Authors: Gabriella Lauriero; Lilia Abbad; Mirco Vacca; Giuseppe Celano; Jonathan M Chemouny; Maria Calasso; Laureline Berthelot; Loreto Gesualdo; Maria De Angelis; Renato C Monteiro Journal: Front Immunol Date: 2021-10-12 Impact factor: 7.561